HOME >> MEDICINE >> NEWS
JCI table of contents: May 4, 2006

AUTHOR CONTACT:
Paul J. Bryce
Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Phone: (312) 503-0077; Fax: (312) 503-0078; E-mail: p-bryce@northwestern.edu.

View the PDF of this article at: https://www.the-jci.org/article.php?id=26150

BONE BIOLOGY

Peptide inhibitor may prevent bone loss in osteoporosis

Two molecules known as RANK and TNFR promote the differentiation of osteoclasts cells that are responsible for the breakdown of bone. This process occurs in healthy individuals as part of the constant renewal of the bone that makes up our skeleton, and it occurs at an increased rate in individuals with diseases such as osteoporosis, rheumatoid arthritis, and periodontal disease. A site on TNFR that is critical for the binding of activating molecules is also conserved, in part, on RANK. In a study appearing online on May 4 in advance of print publication in the June issue of the Journal of Clinical Investigation, Roland Baron and colleagues from Yale University School of Medicine show that mimicking a critical loop of TNFR and RANK with a small cyclic peptide allows the inhibition of RANK ligandinduced bone breakdown and resorption in mouse models of osteoporosis. The authors used molecular modeling to demonstrate the exact region where the peptide binds and interferes with RANK signaling. These findings pave the way for the development of new strategies for designing peptide as well as nonpeptide inhibitors of RANK ligandinduced osteoclast-mediated bone loss, which is a key pathway in the mechanisms at work in many bone and joint diseases.

TITLE: A TNF receptor loop peptide mimic blocks RANK ligandinduced signaling, bone resorption, and bone loss

AUTHOR CONTACT:
Roland Baron
Yale University School of Medicine, New Haven, Connecticut, USA.
'"/>

Contact: Brooke Grindlinger
press_releases@the-jci.org
212-342-9006
Journal of Clinical Investigation
4-May-2006


Page: 1 2 3 4

Related medicine news :

1. International symposium on fruit, vegetables headed for Houston
2. Stevens Roundtable: Health, Technology & Society, July 11
3. FDA approves ZYFLO CR extended-release tablets for chronic treatment of asthma
4. Once-fatal metabolic disorders treatable, says Stanford/Packard researcher
5. Clinical review -- A psychological approach to the management of irritable bowel syndrome
6. JCI table of contents -- May 17, 2007
7. JCI table of contents: May 10, 2007
8. New treatments needed for irritable bowel syndrome
9. JCI table of contents: May 1, 2007
10. Americans still not eating enough fruits and vegetables, according to 2 recent studies
11. Slow-release morphine reduces level of intractable cough

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/9/2016)... ... 2016 , ... The Pennsylvania Athletic Trainers’ Society (PATS) aired ... of 2016. The program was made possible by a Pennsylvania Department of Health ... and Human Services Administration. The broadcast, Use Your Head: Properly Managing Sport ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital ... and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation ... a few hospitals and facilities have earned this distinction. This is the second ...
(Date:12/8/2016)... ... 08, 2016 , ... Russ DiGilio , founder and ... #QuackGivesBack campaign which supported local breast cancer organizations during National Breast Cancer Awareness ... Back initiative, and we’re very pleased with the participation in every franchisee’s ...
(Date:12/8/2016)... PLAINS, N.Y., and JENNERSVILLE, Pa. (PRWEB) , ... ... ... to announce that Penn Medicine Southern Chester County, a Property owned by an ... The $23 million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s leading digital and ... with Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media Group ... said, “CURE Media Group is honored to team up with Upstage Lung Cancer in ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)...  Valeant Pharmaceuticals International, Inc. (NYSE: ... positive results from a Phase 3, multicenter double-blind, ... and efficacy of IDP-118 (halobetasol propionate and tazarotene) ... Within the Phase 3 study of ... IDP-118 showed statistical significance to vehicle with a ...
(Date:12/8/2016)... Mederi Therapeutics Inc . hat die behördliche Zulassung durch ... gastroösophageale Refluxerkrankung (GERD) – in China angekündigt. ... ... Live Stretta procedure performed and broadcast during ... Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)... -- Boehringer Ingelheim announced today that it has been recognized ... the ninth time that the company received a perfect ... to Work for LGBT Equality. Administered by the Human ... report on corporate policies and practices related to workplace ... "We are committed to creating an ...
Breaking Medicine Technology:
Cached News: